Abstract
Increases in plasma of β-amyloids (Aβ) and tau proteins have been noted in patients with Alzheimer’s dementia (AD). Our study investigated the associations of plasma Aβ and tau proteins with dementia in stroke patients. This cross-sectional study recruited 24 controls (mean age: 67.4 ± 7.5 years, 33.3% male), 27 stroke patients without dementia (mean age: 70.7 ± 6.9 years, 60.7% male), 34 stroke patients with dementia (mean age: 78.3 ± 5.3 years, 45.5% male, Clinical Dementia Ranking (CDR): 1.46 ± 0.63), and 21 AD patients (mean age: 77.1 ± 9.1 years, 42.9% male, CDR: 1.43 ± 0.60) from a medical center. Dementia was defined as a CDR scale score of ≥ 1. The plasma levels of Aβ-40, Aβ-42, and tau were analyzed using immunomagnetic reduction. One-way analysis of variance was used to compare the differences in measured protein levels between the groups. The results indicated that plasma levels of tau and Aβ-42, but not Aβ-40, in stroke patients were significantly higher than in the controls. After adjustment for age, sex, diabetes mellitus, hypertension, and hyperlipidemia, only plasma level of Aβ-42 remained significantly higher in stroke patients with dementia than in those without dementia (OR 1.85, 1.25–2.75, p = 0.002). In summary, our results suggest that plasma Aβ-42 is a potential biomarker for dementia in stroke patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chiu, M. J., Yang, S. Y., Horng, H. E., Yang, C. C., Chen, T. F., Chieh, J. J., et al. (2013). Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s disease. ACS Chemical Neuroscience, 4(12), 1530–1536. https://doi.org/10.1021/cn400129p.
Feigin, V. L., Mensah, G. A., Norrving, B., Murray, C. J., & Roth, G. A. (2015). Atlas of the Global Burden of Stroke (1990–2013): The GBD 2013 Study. Neuroepidemiology, 45(3), 230–236. https://doi.org/10.1159/000441106.
Huang, K. L., Lin, K. J., Ho, M. Y., Chang, Y. J., Chang, C. H., Wey, S. P., et al. (2012). Amyloid deposition after cerebral hypoperfusion: Evidenced on [(18)F]AV-45 positron emission tomography. Journal of the Neurological Sciences, 319(1–2), 124–129. https://doi.org/10.1016/j.jns.2012.04.014.
Iadecola, C. (2013). The pathobiology of vascular dementia. Neuron, 80(4), 844–866. https://doi.org/10.1016/j.neuron.2013.10.008.
Iqbal, K., Liu, F., & Gong, C. X. (2016). Tau and neurodegenerative disease: The story so far. Nature Reviews Neurology, 12(1), 15–27. https://doi.org/10.1038/nrneurol.2015.225.
Jack, C. R. Jr., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., et al. (2011). Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 257–262. https://doi.org/10.1016/j.jalz.2011.03.004.
Mattson, M. P. (2004). Pathways towards and away from Alzheimer’s disease. Nature, 430(7000), 631–639. https://doi.org/10.1038/nature02621.
Roman, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., et al. (1993). Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 43(2), 250–260.
Tang, S. C., Jen, H. I., Lin, Y. H., Hung, C. S., Jou, W. J., Huang, P. W., et al. (2015). Complexity of heart rate variability predicts outcome in intensive care unit admitted patients with acute stroke. Journal of Neurology, Neurosurgery, and Psychiatry, 86(1), 95–100.
Tang, S. C., Wang, Y. C., Li, Y. I., Lin, H. C., Manzanero, S., Hsieh, Y. H., et al. (2013). Functional role of soluble receptor for advanced glycation end products in stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(3), 585–594. https://doi.org/10.1161/atvbaha.112.300523.
Tang, S. C., Yang, K. C., Hu, C. J., Chiou, H. Y., Wu, C. C., & Jeng, J. S. (2017). Elevated plasma level of soluble form of RAGE in ischemic stroke patients with dementia. Neuromolecular Medicine, 19(4), 579–583. https://doi.org/10.1007/s12017-017-8471-9.
Thiel, A., Cechetto, D. F., Heiss, W. D., Hachinski, V., & Whitehead, S. N. (2014). Amyloid burden, neuroinflammation, and links to cognitive decline after ischemic stroke. Stroke, 45(9), 2825–2829. https://doi.org/10.1161/strokeaha.114.004285.
Tierney, M. C., Snow, W. G., & Fisher, R. H. (1989). Dementia diagnosis. Neurology, 39(11), 1559–1560.
Van Nostrand, W. E., Davis, J., Previti, M. L., & Xu, F. (2012). Clearance of amyloid-beta protein deposits in transgenic mice following focal cerebral ischemia. Neurodegenerative Diseases, 10(1–4), 108–111. https://doi.org/10.1159/000334763.
Yang, S. Y., Chiu, M. J., Chen, T. F., Lin, C. H., Jeng, J. S., Tang, S. C., et al. (2017). Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases. Scientific Reports, 7(1), 9304. https://doi.org/10.1038/s41598-017-09009-3.
Ye, B. S., Seo, S. W., Kim, J. H., Kim, G. H., Cho, H., Noh, Y., et al. (2015). Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. Neurology, 85(19), 1687–1693. https://doi.org/10.1212/wnl.0000000000002097.
Acknowledgements
The authors thank the 3rd core facility at National Taiwan University Hospital for support.
Funding
This work was supported by Taiwan Ministry of Science and Technology Grant (105-2314-B-002-001).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Tang, SC., Yang, KC., Chen, CH. et al. Plasma β-Amyloids and Tau Proteins in Patients with Vascular Cognitive Impairment. Neuromol Med 20, 498–503 (2018). https://doi.org/10.1007/s12017-018-8513-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-018-8513-y